Effects of Teclistamab and Talquetamab on Soluble BCMA Levels In patients with Relapsed/refractory Multiple Myeloma

Overview

Journal Blood Adv

Specialty Hematology

Date 2022 Aug 25

PMID 36006441

Authors

Suzette Girgis

Shun Xin Wang Lin

Kodandaram Pillarisetti

Raluca Verona

Diego Vieyra

Tineke Casneuf

Damien Fink

Xin Miao

Yang Chen

Tara Stephenson

Arnob Banerjee

Brandi W Hilder

Jeffery Russell

Jeffrey Infante

Yusri Elsayed

Jennifer Smit

Jenna D Goldberg

Affiliations

Soon will be listed here.

Citing Articles

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.

Sorgiovanni I, Del Giudice M, Galimberti S, Buda G Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005960 PMC: 11859432. DOI: 10.3390/ph18020145.

Predictive Role of Soluble B-Cell Maturation Antigen in Short-Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study.

Caponi L, Del Giudice M, Botti A, Ursino S, Gennari A, Paolicchi A J Clin Lab Anal. 2025; 39(4):e25151.

PMID: 39817468 PMC: 11848191. DOI: 10.1002/jcla.25151.

T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice.

OBrien N, Mueller J, Broske A, Attig J, Osl F, Crisand C MAbs. 2024; 17(1):2440578.

PMID: 39686589 PMC: 11654707. DOI: 10.1080/19420862.2024.2440578.

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I Blood. 2024; 145(2):202-219.

PMID: 39476124 PMC: 11738037. DOI: 10.1182/blood.2024025987.

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P Blood Cancer Discov. 2024; 6(1):38-54.

PMID: 39441177 PMC: 11707513. DOI: 10.1158/2643-3230.BCD-24-0118.

References

Yu B, Jiang T, Liu D . BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020; 13(1):125. PMC: 7499842. DOI: 10.1186/s13045-020-00962-7. View

Ghermezi M, Li M, Vardanyan S, Harutyunyan N, Gottlieb J, Berenson A . Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2016; 102(4):785-795. PMC: 5395119. DOI: 10.3324/haematol.2016.150896. View

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Ali S, Shi V, Maric I, Wang M, Stroncek D, Rose J . T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016; 128(13):1688-700. PMC: 5043125. DOI: 10.1182/blood-2016-04-711903. View

Durie B, Miguel J, Blade J, Rajkumar S . Clarification of the definition of complete response in multiple myeloma. Leukemia. 2015; 29(12):2416-7. DOI: 10.1038/leu.2015.290. View

Pont M, Hill T, Cole G, Abbott J, Kelliher J, Salter A . γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134(19):1585-1597. PMC: 6871311. DOI: 10.1182/blood.2019000050. View

Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y . Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020; 4(18):4538-4549. PMC: 7509877. DOI: 10.1182/bloodadvances.2020002393. View

Huehls A, Coupet T, Sentman C . Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2014; 93(3):290-6. PMC: 4445461. DOI: 10.1038/icb.2014.93. View

10.

Bujarski S, Goldwater M, Regidor B, Jew S, Daniely D, Swift R . Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma. Eur J Haematol. 2021; 107(3):318-323. DOI: 10.1111/ejh.13666. View

11.

Shah N, Chari A, Scott E, Mezzi K, Usmani S . B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020; 34(4):985-1005. PMC: 7214244. DOI: 10.1038/s41375-020-0734-z. View

12.

Usmani S, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021; 398(10301):665-674. DOI: 10.1016/S0140-6736(21)01338-6. View

13.

Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt T, Raderer M . Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012; 42(9):953-60. DOI: 10.1111/j.1365-2362.2012.02679.x. View

14.

OConnor B, Raman V, Erickson L, Cook W, Weaver L, Ahonen C . BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004; 199(1):91-8. PMC: 1887725. DOI: 10.1084/jem.20031330. View

15.

Brudno J, Maric I, Hartman S, Rose J, Wang M, Lam N . T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol. 2018; 36(22):2267-2280. PMC: 6067798. DOI: 10.1200/JCO.2018.77.8084. View

16.

Durie B, Harousseau J, Miguel J, Blade J, Barlogie B, Anderson K . International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-73. DOI: 10.1038/sj.leu.2404284. View

17.

Laurent S, Hoffmann F, Kuhn P, Cheng Q, Chu Y, Schmidt-Supprian M . γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015; 6:7333. PMC: 4490565. DOI: 10.1038/ncomms8333. View

18.

Rajkumar S, Harousseau J, Durie B, Anderson K, Dimopoulos M, Kyle R . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-5. PMC: 3710442. DOI: 10.1182/blood-2010-10-299487. View

19.

Frigyesi I, Adolfsson J, Ali M, Christophersen M, Johnsson E, Turesson I . Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014; 123(9):1336-40. DOI: 10.1182/blood-2013-09-529800. View

20.

Avery D, Kalled S, Ellyard J, Ambrose C, Bixler S, Thien M . BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003; 112(2):286-97. PMC: 164292. DOI: 10.1172/JCI18025. View